CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2033-03-17 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2026-10-16 | Bono Raquel C. Director | Grant or award | +78,800 | 78,800 | ||
| 2026-10-16 | Bono Raquel C. Director | Grant or award · Stock Option (right to buy) | +157,400 | 157,400 | ||
| 2026-07-16 | Finney Kevin Director | Grant or award | +39,400 | 244,171 | ||
| 2026-07-16 | Finney Kevin Director | Grant or award · Stock Options (right to buy) | +78,700 | 78,700 | ||
| 2026-07-16 | BREITMEYER JAMES B Director | Grant or award | +8,315 | 87,115 | ||
| 2026-07-16 | BREITMEYER JAMES B Director | Grant or award · Stock Options (right to buy) | +16,610 | 16,610 | ||
| 2026-07-16 | HERON ELAINE J Director | Grant or award | +39,400 | 135,966 | ||
| 2026-07-16 | HERON ELAINE J Director | Grant or award · Stock Options (right to buy) | +78,700 | 78,700 | ||
| 2026-07-16 | Watson W. Mark Director | Grant or award | +39,400 | 173,525 | ||
| 2026-07-16 | Watson W. Mark Director | Grant or award · Stock Options (right to buy) | +78,700 | 78,700 | ||
| 2026-07-16 | Wheadon David E. Director | Grant or award | +39,400 | 86,150 | ||
| 2026-07-16 | Wheadon David E. Director | Grant or award · Stock Options (right to buy) | +78,700 | 78,700 | ||
| 2026-05-22 | Watson W. Mark Director | Purchase | +10,000 | $0.65 | $7K | 134,125 |
| 2026-05-19 | Grasman Jeroen Nicolaas Chief Financial Officer | Shares withheld for taxes | −31,395 | $0.61 | $19K | 545,605 |
| 2026-04-23 | BREITMEYER JAMES B Director | Grant or award | +78,800 | 78,800 | ||
| 2026-04-23 | BREITMEYER JAMES B Director | Grant or award · Stock Option (right to buy) | +157,400 | 157,400 | ||
| 2026-03-28 | Tucker Sean SVP, Chief Scientific Officer | Shares withheld for taxes | −3,924 | $0.65 | $3K | 882,811 |
| 2026-03-28 | Cummings James F. Chief Medical Officer | Shares withheld for taxes | −3,292 | $0.65 | $2K | 924,177 |
| 2026-03-24 | Berg Edward B SVP, General Counsel | Shares withheld for taxes | −36,418 | $0.69 | $25K | 755,368 |
Page 1 of 10 · 198 trades